UBS resumed coverage on QuidelOrtho with a new price target
$QDEL
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
UBS resumed coverage of QuidelOrtho with a rating of Neutral and set a new price target of $50.00 from $42.00 previously